Personal information

Verified email addresses

Verified email domains

Spain

Biography

From 2011 to 2015, I pursued a degree in Biomedicine at the University of Seville, culminating in my Bachelor's Thesis within the "Infectious Diseases" Research Group at the Institute of Biomedicine of Seville (IBIS). My primary focus was the characterization of outer membrane vesicles in Acinetobacter baumannii. Subsequently, I advanced my scientific career by relocating to the University of Konstanz in Germany, where I completed a Master's Degree with a specialization in immunology. Progressing further, I joined Dr. Groettrup's Immunology group for my Ph.D. studies, investigating the role of immunoproteasome inhibitors and their upstream element VCP/p97. My doctoral research, titled "Targeting the Immunoproteasome and VCP/p97 in Autoimmune Disorders and Viral Infections," concluded in 2022 with the distinction of Magna Cum Laude. Positive outcomes in the thesis paved the way for Kezar Life Science to initiate clinical trials for inflammatory myositis. My dissertation work resulted in three manuscripts published as lead author in high-impact peer-reviewed journals, demonstrating the therapeutic benefits of immunoproteasome inhibitors in alleviating myositis and psoriasis symptoms. Furthermore, I characterized the immune responses to viral infections in Lymphocytic choriomeningitis virus (LCMV)-infected mice after VCP/p97 inhibition. Notably, this research unveiled a previously unknown toxicity associated with VCP/p97 inhibition in viral infection.
During my Ph.D., I independently led my research, excelling in crafting hypotheses, defining objectives, and innovating techniques. As the sole executor of experimental work, I concurrently handled multiple projects. In the role of principal scientist for murine models, I took charge of formulating and approving animal research protocols, ensuring optimal animal welfare. Moreover, during my Ph.D. studies, I integrated my interest in education. I actively participated in the theoretical and practical programs for the Master's portfolio in the Vertiefungskurs Advanced Laboratory Course Immunology course at the University of Konstanz for Biological and Life Sciences Masters.
Additionally, I supervised a bachelor thesis (David Lacher) and two internal internships for graduated students in the context of the advanced laboratory course in the Life Science master portfolio (Nina Schumann and Marleen Herbinger). Following several years spent abroad, I transitioned into the esteemed research group led by Dr. Sanchez Cespedes at the Institute of Biomedicine, situated in Seville. Within this role, my focus centered on meticulously analyzing the immunodepressed patients' responses to viral infections. As of January 2024, I am now situated at the Center of Molecular Biology and Regenerative Medicine (CABIMER), under the guidance of Dr. Valle Rosado. Presently, my research endeavors are concentrated on unraveling the intricacies of replication mechanisms and endogenous DNA damage phenomena in the context of Fanconi's anaemia.

Activities

Employment (4)

Universidad de Sevilla: Seville, ES

2024-01 to present | Postdoc (Genetics)
Employment
Source: Self-asserted source
Marta del Rio Oliva

Instituto de Biomedicina de sevilla: Sevilla, Andalucia, ES

2023-07 to 2024-01 (Division of Infectious Diseases, Microbiology and Parasitology)
Employment
Source: Self-asserted source
Marta del Rio Oliva

University of Konstanz: Konstanz, Baden wurrtemberg, DE

2019-01 to 2022-12 | Research associate (Immunology)
Employment
Source: Self-asserted source
Marta del Rio Oliva

University of Konstanz: Konstanz, DE

2018-08 to 2018-12 | Internal scientist (Immunology)
Employment
Source: Self-asserted source
Marta del Rio Oliva

Education and qualifications (3)

University of Konstanz: Konstanz, DE

Life Science Master-Biology specialisation
Education
Source: Self-asserted source
Marta del Rio Oliva

Universidad de Sevilla: Seville, ES

Grado en Biomedicina Basica y experimental
Education
Source: Self-asserted source
Marta del Rio Oliva

University of Konstanz: Konstanz, DE

2022-12 | Doctor in natural sciences, Magna cum laude (Immunology)
Education
Source: Self-asserted source
Marta del Rio Oliva

Funding (3)

Estudio de la tumorogénesis asociada a la deficiencia de la ruta de reparación del DNA Anemia de Fanconi

2023 to 2025 | Grant
University of Seville (Seville, ES)
Source: Self-asserted source
Marta del Rio Oliva

The substrates of FAT10ylation and their proteolytic targeting

2020 to 2023 | Grant
University of Konstanz (Konstanz, DE)
Source: Self-asserted source
Marta del Rio Oliva

Immunoproteasome inhibition on the development of inflammatory myositis

2017 to 2022 | Contract
Kezar Life Sciences (Chicago, US)
Source: Self-asserted source
Marta del Rio Oliva

Works (9)

HMCES corrupts replication fork stability during base excision repair in homologous recombination deficient cells

2024-07-31 | Preprint
Contributors: Peña-Gómez MJ; Yaiza Rodriguez Martin; Marta del Rio Oliva; Jean-Yves Masson; Jose C. Reyes; Iván Rosado
Source: Self-asserted source
Marta del Rio Oliva

Corrigendum: Immunoproteasome inhibition attenuates experimental psoriasis

Frontiers in Immunology
2024-01-16 | Journal article
Part of ISSN: 1664-3224
Contributors: Marta del Rio Oliva; Mark Mellett; Michael Basler
Source: Self-asserted source
Marta del Rio Oliva

Immunoproteasome inhibition attenuates experimental psoriasis

2023-08 | Conference abstract
Contributors: Marta del Rio Oliva
Source: Self-asserted source
Marta del Rio Oliva

Immunoproteasome inhibition attenuates experimental psoriasis

Frontiers in Immunology
2022 | Journal article
EID:

2-s2.0-85145339394

Part of ISSN: 16643224
Contributors: del Rio Oliva, M.; Mellett, M.; Basler, M.
Source: Self-asserted source
Marta del Rio Oliva via Scopus - Elsevier

Targeting the Immunoproteasome and VCP/p97 in Autoimmune Disorders and Viral Infections

2022-12-06 | Dissertation or Thesis
Contributors: Marta del Rio Oliva
Source: Self-asserted source
Marta del Rio Oliva

Valosin-containing protein (VCP/p97) inhibition reduces viral clearance and induces toxicity associated with muscular damage

Cell Death & Disease
2022-12-01 | Journal article
Contributors: Marta del Rio Oliva; Michael Basler
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Effective therapy of polymyositis in mice via selective inhibition of the immunoproteasome

European Journal of Immunology
2022-06-22 | Journal article
Part of ISSN: 0014-2980
Part of ISSN: 1521-4141
Source: Self-asserted source
Marta del Rio Oliva
grade
Preferred source (of 2)‎

Immunoproteasome inhibition in a murine model of polymyositis

2nd Joint Meeting of the German-Society-for-Immunology (DGfl) and the Italian-Society-of-Immunology-Clinical-Immunology-and-Allergology (SIICA)
2019 | Conference abstract
Contributors: Marta del Rio Oliva
Source: Self-asserted source
Marta del Rio Oliva

KZR-616, a First-in-class Selective Inhibitor of the Immunoproteasome, Ameliorates Polymyositis in a Murine Model

Annual Meeting of the American-College-of-Rheumatology (ACR)
Conference abstract
Contributors: Marta del Rio Oliva
Source: Self-asserted source
Marta del Rio Oliva